Sterling Capital Management LLC decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 12.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 7,535 shares of the pharmaceutical company’s stock after selling 1,113 shares during the period. Sterling Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $3,939,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of VRTX. XXI Wealth LLC increased its stake in Vertex Pharmaceuticals by 6.4% in the third quarter. XXI Wealth LLC now owns 502 shares of the pharmaceutical company’s stock valued at $262,000 after purchasing an additional 30 shares in the last quarter. MBL Wealth LLC raised its holdings in shares of Vertex Pharmaceuticals by 5.4% during the third quarter. MBL Wealth LLC now owns 645 shares of the pharmaceutical company’s stock valued at $337,000 after purchasing an additional 33 shares during the period. Strategic Planning Group LLC raised its holdings in shares of Vertex Pharmaceuticals by 4.4% during the third quarter. Strategic Planning Group LLC now owns 19,483 shares of the pharmaceutical company’s stock valued at $10,186,000 after purchasing an additional 817 shares during the period. Brookstone Capital Management raised its holdings in shares of Vertex Pharmaceuticals by 16.4% during the third quarter. Brookstone Capital Management now owns 582 shares of the pharmaceutical company’s stock valued at $304,000 after purchasing an additional 82 shares during the period. Finally, Precedent Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $242,000. Institutional investors own 90.96% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have recently commented on VRTX shares. Canaccord Genuity Group raised their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. Morgan Stanley assumed coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They set an “overweight” rating and a $665.00 price target on the stock. Rothschild & Co Redburn increased their price target on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Barclays raised their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $579.81.
Get Our Latest Stock Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Trading Down 2.1%
VRTX opened at $523.93 on Friday. The company’s fifty day moving average price is $523.52 and its two-hundred day moving average price is $483.25. Vertex Pharmaceuticals Incorporated has a 1-year low of $403.16 and a 1-year high of $560.25. The company has a market cap of $132.97 billion, a price-to-earnings ratio of 30.50, a PEG ratio of 2.51 and a beta of 0.28.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The business had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the business posted $4.52 earnings per share. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.74 earnings per share for the current fiscal year.
Vertex Pharmaceuticals News Summary
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Povetacicept delivered positive Phase 3 results. Vertex said the RAINIER trial met all key endpoints in IgA nephropathy, an immune-mediated kidney disease. The results were published in the New England Journal of Medicine and presented at the American Society of Nephrology meeting, supporting the drug’s potential to become an important commercial product. Vertex Pharmaceuticals Posts Positive Phase 3 Results for Povetacicept
- Positive Sentiment: Vertex plans to seek FDA accelerated approval for povetacicept in IgA nephropathy. Regulatory progress could bring a new revenue source closer and reduce the company’s reliance on its cystic fibrosis franchise. Phase 3 RAINIER Results for Povetacicept
- Positive Sentiment: Pipeline diversification is becoming more credible. About 96% of Vertex’s product sales currently come from cystic fibrosis treatments, but povetacicept and inaxaplin could expand the company into kidney disease. Inaxaplin is viewed as a potential blockbuster, adding longer-term growth optionality. Vertex Pharmaceuticals Pipeline Diversification
- Neutral Sentiment: Vertex highlighted its broader kidney-disease research program at ASN Kidney Week 2026, but the presentations do not appear to add a major new financial forecast beyond the povetacicept results. Vertex ASN Kidney Week 2026 Transcript
- Negative Sentiment: Erste Group Bank slightly reduced its EPS forecasts. The firm cut its FY2026 estimate to $16.65 from $16.68 and its FY2027 estimate to $18.97 from $19.09. While the reductions are small, they may weigh on sentiment and highlight near-term earnings uncertainty. Vertex Pharmaceuticals Analyst Estimates
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.
Featured Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
